Overview

Joy Sharp is a passionate advocate for clients navigating policy and operational decision-making given the legal and regulatory complexities of today’s public health law and policy. With 15 years of experience in the Food and Drug Administration, Joy brings a wealth of specialized legal and regulatory knowledge to the table for regulated industry, particularly manufacturers of drugs, biologics, medical devices and combination products; importers of food and other regulated products; and companies seeking to optimize and market platform technologies, secure supply chains and meet quality expectations. With many years of in-house general business practice experience, advising senior executives on corporate legal policy and in niche aspects of transportation law, Joy is adept at helping clients maneuver challenging situations by providing seasoned legal guidance on regulatory requirements and Agency processes.

FDA Experience

Joy’s tenure with the FDA included service in the Center for Drug Evaluation and Research Office of Pharmaceutical Quality, Office of Policy for Pharmaceutical Quality, Office of Compliance, Office of Food Policy and Response (Office of the Commissioner), the Center for Food Safety and Applied Nutrition and the Office of Regulatory Affairs (Office of Import Operations). 

While at the FDA, Joy advised on many aspects of drug and biological product policy, including inspectional authority, matters of product jurisdiction, scope of statutory authority, and applicability of current regulatory regime to various Agency initiatives (e.g., elements of the Framework for Regulatory Advanced Manufacturing (FRAME) initiative (distributed manufacturing, point of care, interplay with in-process testing policy and other complex regulatory matters)); the Agency’s platform technology designation program; and quality metrics and quality management maturity initiatives. Joy advised senior imports and field leadership in the areas of imports review process, sampling strategy, import alerts and administrative detention, prior notice, and Automated Commercial Environment data set and process requirements. Joy also supported implementation of the FDA’s New Era of Smarter Food Safety, participated at a senior level in the drafting and implementation of the Food Safety Modernization Act (FSMA) and its foundational rules and programs, and led the drafting and facilitated publishing of the FDA’s Strategy for the Safety of Imported Food.

Joy is uniquely equipped to support clients in the drug and biologics industries, as her FDA regulatory experience provides insight on Current Good Manufacturing Practice (CGMP) for finished drug (small and large molecule), active pharmaceutical ingredient (API),and excipient manufacturers, as well as on FDA’s use of ICH quality guidelines, foreign and domestic inspectional policy, recall scope and depth, post-marketing reporting, biological product licensing — required elements and review process, quality metrics and quality management maturity initiatives, Good Guidance Practice (GGP), and more. When providing guidance to clients in the food and beverage industries, Joy can tap into her experience with areas including import certification, prior notice, the Food Safety Modernization Act (FSMA), the Preventive Controls and Produce Safety rules, the Foreign Supplier Verification Programs (FSVP), Accredited Third-Party Certification Program, Voluntary Qualified Importer Program (VQIP), traceability and more.

Transportation Experience

Prior to her work with the FDA, Joy spent nearly a decade providing legal guidance in the transportation (air freight-forwarding, ground carriage) and logistics industry. She drafted and implemented the security protocol for 135 distribution centers; advised the fleet safety director for the then-largest private fleet of tractor-trailers in the world; and negotiated vehicle leases, freight-forwarding/logistics contracts and corporate airplane sales.

Personal Interests

Joy is an accomplished classical pianist and is active in her beloved piano club. When there is no piano around, Joy likes to read, garden and spend time with her family. 

Related Policy, Advocacy, and Consulting Services

Related Industries

Related Topics

Credentials

Bar Admissions

Maryland
District of Columbia

Court Admissions

U.S. Supreme Court

Education

University of Maryland School of Law
J.D. (1993)

Johns Hopkins University
Bachelor's Degree in International Relations (1990)

Insights & Events

Latest
最新 January 2025

FDA Issues Detailed Guidance for Biopharma Industry on What Information to Provide to FDA About Use of AI Models

A Seven-Step Process and Detailed Recommendations for Submissions
6 min read  
最新 January 2025

FDA Makes Draft Guidance Available on Lifecycle Management and Marketing Submission Recommendations for AI-Enabled Device Software Functions and Requests Industry Input

6 min read  
最新 December 2024

The Prospects of Dr. Martin Makary and RFK Jr. at HHS, Potential Pharma Tariffs, and EU Guidance on Ethylene Oxide

Biopharma & Medical Devices Briefing
7 min read  
Recorded Webinar December 04, 2024

One Year After Biden’s AI Executive Order: AI Compliance Programs & What Health & Life Sciences Companies Should Know - Webinar

1 min read  
最新 September 2024

Recap of the FDA and CTTI Public Workshop on AI in Drug Development

3 min read  
最新 August 2024

AI After the Election: Potential Differences Between a Harris Administration and a Second Trump Administration for Artificial Intelligence Regulation

8 min read  
Recorded Webinar August 28, 2024 CLE

Navigating the New Era of Cosmetic Regulation: Key Insights on MoCRA Compliance - Webinar

The Legal Compact Webinar Series
1 min read  
News June 2024

Cross-Practice Faegre Drinker Team Represents Surmodics in Acquisition Agreement

2 min read  
Speaking Engagement Recap June 07, 2024

FDA Surveillance in a Post-MoCRA World - Scottsdale, AZ

1 min read  
Press Release October 2023

Faegre Drinker Adds Leading FDA Regulatory Attorney Joy Sharp in Washington, D.C.

2 min read  
Insights
最新 January 2025

FDA Issues Detailed Guidance for Biopharma Industry on What Information to Provide to FDA About Use of AI Models

A Seven-Step Process and Detailed Recommendations for Submissions
6 min read  
最新 January 2025

FDA Makes Draft Guidance Available on Lifecycle Management and Marketing Submission Recommendations for AI-Enabled Device Software Functions and Requests Industry Input

6 min read  
最新 December 2024

The Prospects of Dr. Martin Makary and RFK Jr. at HHS, Potential Pharma Tariffs, and EU Guidance on Ethylene Oxide

Biopharma & Medical Devices Briefing
7 min read  
最新 September 2024

Recap of the FDA and CTTI Public Workshop on AI in Drug Development

3 min read  
最新 August 2024

AI After the Election: Potential Differences Between a Harris Administration and a Second Trump Administration for Artificial Intelligence Regulation

8 min read  
最新 August 2024

The Dawn of a New Day — FDA Bases Regulatory Decision on ML-Generated Data

3 min read  
最新 July 2024

Artificial Intelligence Briefing: White House Announces the Completion of Agency Actions Required by the AI Executive Order

12 min read  
最新 July 2024

NIST Makes Good on Biden’s Executive Order on AI, Delivering Algorithm-Testing Software and Multiple AI-Related Guidance Documents to the Public

4 min read  
最新 July 2024

Worried About Misinformation? FDA Is Too. Here’s What You Should Know.

5 min read  
最新 June 2024

FDA Grants Small Dispensers More Time, but Nobody Else

5 min read  
Other Perspectives